Alves P. Correa

3900 Bandeirantes Avenue
Ribeirao Preto, SP 14049900, Brazil

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

miR-512-3p as a Potential Biomarker of Poor Outcome in Pediatric Medulloblastoma.

miR-512-3p as a Potential Biomarker of Poor Outcome in Pediatric Medulloblastoma.

Journal: Cerebellum (London, England)

Published: February 25, 2025

Identifying prognostic hub genes and key pathways in pediatric adrenocortical tumors through RNA sequencing and Co-expression analysis.

Identifying prognostic hub genes and key pathways in pediatric adrenocortical tumors through RNA sequencing and Co-expression analysis.

Journal: Molecular and cellular endocrinology

Published: July 24, 2024

Analysis of miR-483-3p and miR-630 expression profile in pediatric adrenocortical tumors and the effect of their modulation on adrenal tumorigenesis in vitro.

Analysis of miR-483-3p and miR-630 expression profile in pediatric adrenocortical tumors and the effect of their modulation on adrenal tumorigenesis in vitro.

Journal: Molecular and cellular endocrinology

Published: June 18, 2024

Low PRKAB2 Expression Is Associated with Poor Outcomes in Pediatric Adrenocortical Tumors, and Treatment with Rottlerin Increases the PRKAB2 Level and Inhibits Tumorigenic Aspects in the NCI-H295R Adrenocortical Cancer Cell Line.

Low PRKAB2 Expression Is Associated with Poor Outcomes in Pediatric Adrenocortical Tumors, and Treatment with Rottlerin Increases the PRKAB2 Level and Inhibits Tumorigenic Aspects in the NCI-H295R Adrenocortical Cancer Cell Line.

Journal: Cancers

Published: December 22, 2023

Musashi-1 regulates cell cycle and confers resistance to cisplatin treatment in Group 3/4 medulloblastomas cells.

Musashi-1 regulates cell cycle and confers resistance to cisplatin treatment in Group 3/4 medulloblastomas cells.

Journal: Human cell

Published: June 05, 2023

MicroRNA-149-3p expression correlates with outcomes of adrenocortical tumor patients and affects proliferation and cell cycle progression of H295A adrenocortical cancer cell line.

MicroRNA-149-3p expression correlates with outcomes of adrenocortical tumor patients and affects proliferation and cell cycle progression of H295A adrenocortical cancer cell line.

Journal: Human cell

Published: April 20, 2022

MicroRNA expression profile predicts prognosis of pediatric adrenocortical tumors.

MicroRNA expression profile predicts prognosis of pediatric adrenocortical tumors.

Journal: Pediatric blood & cancer

Published: October 04, 2021

Identification of ITPR1 as a Hub Gene of Group 3 Medulloblastoma and Coregulated Genes with Potential Prognostic Values.

Identification of ITPR1 as a Hub Gene of Group 3 Medulloblastoma and Coregulated Genes with Potential Prognostic Values.

Journal: Journal of molecular neuroscience : MN

Published: September 13, 2021

Clinical Prognostic Implications of Wnt Hub Genes Expression in Medulloblastoma.

Clinical Prognostic Implications of Wnt Hub Genes Expression in Medulloblastoma.

Journal: Cellular and molecular neurobiology

Published: July 13, 2021

Molecular characterization of Wnt pathway and function of β-catenin overexpression in medulloblastoma cell lines.

Molecular characterization of Wnt pathway and function of β-catenin overexpression in medulloblastoma cell lines.

Journal: Cytotechnology

Published: June 01, 2017

Erratum to: The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveals BATF2 as a poor prognostic marker for childhood medulloblastoma.

Erratum to: The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveals BATF2 as a poor prognostic marker for childhood medulloblastoma.

Journal: Investigational new drugs

Published: December 01, 2016

The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveals BATF2 as a poor prognostic marker for childhood medulloblastoma.

The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveals BATF2 as a poor prognostic marker for childhood medulloblastoma.

Journal: Investigational new drugs

Published: August 18, 2016

Showing 1-12 of 12

Last Updated: 09/26/2026